iPSCtechnology has made significant contributions to the biologists’ toolbox andwill continue to advance the frontiers of iPS cell research. Recently, CynataTherapeutics (ASX:CYP) commenced the world’s first clinical trial involvingan allogeneic iPSC-derived therapeutic product, which it derived from CDI’siPSCs. Similarly, many researches are investigating methods to enhance thefunctionality of terminally differentiated cells types.
CYP Price at posting:
$1.59 Sentiment: Buy Disclosure: Held
